Dengvaxia: the world’s first vaccine for prevention of secondary dengue
Therapeutic Advances in Vaccines and Immunotherapy, 2021 The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV)
Danielle Tully, Carrie L. Griffiths
doaj +1 more source
Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. [PDF]
, 2013 BACKGROUND: Malaria remains the leading cause of morbidity and mortality in sub-Saharan Africa despite tools currently available for its control. Making malaria vaccine available for routine use will be a major hallmark, but its acceptance by community ...
A Bingham +30 more
core +2 more sources
The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models. [PDF]
, 2016 Toll-like receptors (TLRs) play an important role in the innate and adaptive immune responses to pathogens, and are the target of new vaccine adjuvants.
Bates, PA +4 more
core +7 more sources
Modelling population-level impact to inform target product profiles for childhood malaria vaccines
BMC Medicine, 2018 Background The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot implementation program.
Alexandra B. Hogan +4 more
doaj +1 more source
Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine [PDF]
, 2001 The efficacy of a muramidase-released protein (MRP) and extracellular factor (EF) vaccine in preventing infection and disease in pigs challenged either with a homologous or a heterologous Streptococcus suis serotype 2 strain (MRP EF ) was compared with ...
Smith, H.E. +3 more
core +2 more sources
Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. [PDF]
, 2011 BACKGROUND\ud \ud An effective malaria vaccine, deployed in conjunction with other malaria interventions, is likely to substantially reduce the malaria burden. Efficacy against severe malaria will be a key driver for decisions on implementation.
Amanda Leach +18 more
core +4 more sources
EClinicalMedicineSummary: Background: Rotavirus is the leading cause of diarrhoea worldwide, particularly affecting young children. While national rotavirus immunization programs have reduced rotavirus morbidity and mortality, vaccine performance varies considerably ...
Ottavia Prunas +11 more
doaj +1 more source
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. [PDF]
PLoS ONE, 2017 Although the HVTN 505 DNA/recombinant adenovirus type 5 vector HIV-1 vaccine trial showed no overall efficacy, analysis of breakthrough HIV-1 sequences in participants can help determine whether vaccine-induced immune responses impacted viruses that ...
Allan C deCamp +47 more
doaj +1 more source
Unwarranted optimism about vaccine efficacy [PDF]
BMJ, 2020 Interim results from phase III trials of the vaccine developed by the University of Oxford and AstraZeneca were announced through press releases on 23 November. Much has been made of an apparent difference in efficacy between the intended regimen (two full doses of the vaccine) and another regimen (a half dose followed by a full dose).
Skegg, David, Pearce, Neil
openaire +2 more sources
Vaccines in Current Culture: The HPV Vaccine Controversy [PDF]
, 2020 The use of vaccinations has drastically decreased mortality and morbidity rates related to infectious disease and has become an intrinsic part of modern health care.
Johnston, Alyssa
core +1 more source